168 related articles for article (PubMed ID: 36089921)
1. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC.
Jing W; Xu T; Wu L; Lopez PB; Grassberger C; Ellsworth SG; Mohan R; Hobbs BP; Blumenschein GR; Tu J; Altan M; Lee P; Liao Z; Lin SH
JTO Clin Res Rep; 2022 Sep; 3(9):100391. PubMed ID: 36089921
[TBL] [Abstract][Full Text] [Related]
2. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.
Thor M; Shepherd AF; Preeshagul I; Offin M; Gelblum DY; Wu AJ; Apte A; Simone CB; Hellmann MD; Rimner A; Chaft JE; Gomez DR; Deasy JO; Shaverdian N
Radiother Oncol; 2022 Feb; 167():158-164. PubMed ID: 34942280
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study.
Jing W; Liu Y; Zhu H; Welsh J; Gandhi S; Jeter M; Nguyen Q; Chen AB; O'Reilly M; Liao Z; Chang JY; Lee P; Lin SH
Clin Transl Radiat Oncol; 2021 May; 28():54-61. PubMed ID: 33778173
[TBL] [Abstract][Full Text] [Related]
6. Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer.
Pasquier C; Chaltiel L; Massabeau C; Rabeau A; Lebas L; Lusque A; Texier JS; Moyal EC; Mazières J; Khalifa J
Front Oncol; 2023; 13():1186479. PubMed ID: 37397359
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.
Vansteenkiste JF; Naidoo J; Faivre-Finn C; Özgüroğlu M; Villegas A; Daniel D; Murakami S; Hui R; Lee KH; Cho BC; Kubota K; Broadhurst H; Wadsworth C; Newton M; Thiyagarajah P; Antonia SJ
JTO Clin Res Rep; 2024 Mar; 5(3):100638. PubMed ID: 38455595
[TBL] [Abstract][Full Text] [Related]
8. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab After Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data.
Jang JY; Song SY; Shin YS; Kim HU; Choi EK; Kim SW; Lee JC; Lee DH; Choi CM; Yoon S; Kim SS
Cancer Res Treat; 2024 Jan; ():. PubMed ID: 38228082
[TBL] [Abstract][Full Text] [Related]
10. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
Verschueren MV; Dijs T; Gulikers JL; Veelen AV; Croes S; Hendriks LE; Smit AA; Bloem LT; Egberts AC; van de Garde EM; Peters BJ
Immunotherapy; 2023 Aug; 15(11):839-851. PubMed ID: 37291888
[TBL] [Abstract][Full Text] [Related]
12. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Vokes EE; Mornex F; Sezer A; Cheng Y; Fang J; Baz DV; Cil T; Adjei AA; Ahn MJ; Barlesi F; Felip E; Garon EB; Audhuy F; Ito R; Sato M; Eggleton SP; Martin CM; Reck M; Robinson CG; Paz-Ares L
J Thorac Oncol; 2024 Feb; 19(2):285-296. PubMed ID: 37797733
[TBL] [Abstract][Full Text] [Related]
13. Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC.
Kuge T; Shiroyama T; Tamiya A; Tamiya M; Kanazu M; Kinehara Y; Tanaka T; Morimura O; Taniguchi Y; Niki T; Tetsumoto S; Hayashi K; Nishino K; Nagatomo I; Kumanogoh A
JTO Clin Res Rep; 2023 May; 4(5):100505. PubMed ID: 37284296
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T; Tateishi K; Komatsu M; Sonehara K; Wasamoto S; Koyama S; Yoshiike F; Hama M; Nishie K; Kondo D; Agatsuma T; Kato A; Takata M; Kanda S; Hanaoka M; Koizumi T
Thorac Cancer; 2022 Jul; 13(14):2031-2040. PubMed ID: 35616056
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.
Cho Y; Kim Y; Chamseddine I; Lee WH; Kim HR; Lee IJ; Hong MH; Cho BC; Lee CG; Cho S; Kim JS; Yoon HI; Grassberger C
Radiother Oncol; 2022 Mar; 168():1-7. PubMed ID: 35033601
[TBL] [Abstract][Full Text] [Related]
18. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
Faivre-Finn C; Vicente D; Kurata T; Planchard D; Paz-Ares L; Vansteenkiste JF; Spigel DR; Garassino MC; Reck M; Senan S; Naidoo J; Rimner A; Wu YL; Gray JE; Özgüroğlu M; Lee KH; Cho BC; Kato T; de Wit M; Newton M; Wang L; Thiyagarajah P; Antonia SJ
J Thorac Oncol; 2021 May; 16(5):860-867. PubMed ID: 33476803
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC.
Shaverdian N; Offin M; Shepherd AF; Hellmann MD; Gomez DR; Chaft JE; Rimner A
JTO Clin Res Rep; 2021 Jul; 2(7):100197. PubMed ID: 34590042
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.
Mehra R; Yong C; Seal B; van Keep M; Raad A; Zhang Y
J Natl Compr Canc Netw; 2021 Feb; 19(2):153-162. PubMed ID: 33545688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
